CT in the prediction of margin-negative resection in par neoadjuvant treatment: a systematic review and meta-a

European Radiology 31, 3383-3393

DOI: 10.1007/s00330-020-07433-0

Citation Report

#	Article	IF	CITATIONS
1	Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma. Journal of the Korean Society of Radiology, 2021, 82, 315.	0.1	0
2	CT-diagnosed extra-pancreatic extension of pancreatic ductal adenocarcinoma is a more reliable prognostic factor for survival than pathology-diagnosed extension. European Radiology, 2022, 32, 22-33.	2.3	9
3	Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?. Cancers, 2021, 13, 4396.	1.7	4
4	Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. European Radiology, 2022, 32, 3799-3807.	2.3	4
5	Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Journal of Magnetic Resonance Imaging, 2022, , .	1.9	3
6	Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified?. Annals of Surgical Oncology, 2022, , 1.	0.7	3
7	Prediction of Marginâ€Negative Resection of Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy: Diagnostic Performance of NCCN Criteria for Resection vs. CTâ€Determined Resectability. Journal of Hepato-Biliary-Pancreatic Sciences, 0, , .	1.4	1
8	Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?. Cancers, 2022, 14, 3453.	1.7	4
9	Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI): prospective pilot study. Langenbeck's Archives of Surgery, 2022, 407, 3487-3499.	0.8	5
10	Technical Implications for Surgical Resection in Locally Advanced Pancreatic Cancer. Cancers, 2023, 15, 1509.	1.7	2